Six-month Ozempic shortage mostly over after weight-loss craze drained supply
Some diabetes patients found it difficult to secure doses of Novo Nordisk’s treatment after people procured the drug for its off-label obesity effects.
By Emma Court, bloomberg
Novo Nordisk A/S replenished supplies of Ozempic, a treatment for diabetes, after social media-driven enthusiasm over the drug’s use for weight loss led to six months of shortages.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New diabetes drugs changing treatment in the US
For subscribers
Supply issues to continue in 2023, reports Novo Nordisk
For subscribers
